It’s only fair to share… Aficamten C18H19N5O2, 337.4 g/mol FDA 2025, APPROVALS 2025, Myqorzo, 12/19/2025, To treat symptomatic obstructive hypertrophic cardiomyopathy CK-3773274, B1I77MH6K1, BAY-3723113; CK 3773274; CK 274; MYQORZO N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methylpyrazole-4-carboxamide Aficamten, sold under the brand name Myqorzo, is a medication used for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.[1] It is a cardiac myosin inhibitor[2] developed by Cytokinetics.[3][4] Aficamten binds directly to the …